Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | JAK1 | P23458 | 3/20 | 0.57 |
| ▸ | TYK2 | P29597 | 3/20 | 0.57 |
| ▸ | JAK3 | P52333 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5875889 | 0.96 | JAK2 (0.53) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL5875791 | 0.85 | TDP1 (0.53) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL5875907 | 0.85 | TDP1 (0.52) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL5875865 | 0.82 | TDP1 (0.47) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL5875897 | 0.81 | TDP1 (0.53) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL2757213 | 0.81 | TDP1 (0.53) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL241242 | 0.81 | TDP1 (0.69) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL4913069 | 0.79 | JAK2 (0.55) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL4910476 | 0.79 | TDP1 (0.58) | JAK2JAK1TYK2JAK3TDP1 | |
| SCHEMBL12457094 | 0.78 | TDP1 (0.56) | JAK2JAK1TYK2JAK3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989387-B2 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-01-24 | — | — | US | disclosed |
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110760-A1 | Nitro and amino substituted topoisomerase agents | TOP1, TOP2A, TOP2B | JAK2 2946/4885JAK1 1485/4885TYK2 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.